Copy to clipboard 
Novo Holdings and TA Associates entered into an agreement to make an investment in Biocomposites. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites.
Biocomposites’ pioneering calcium compounds and specialty polymer products – including STIMULAN, the only calcium matrix carrier platform approved to carry antibiotics into infected and non-infected sites in bone and soft tissue – are used by surgeons in over 100 countries worldwide. With over 30 years of expertise, Biocomposites’ solutions are used in more than one million procedures annually, across multiple specialties including musculoskeletal infection, orthopedics, trauma, spine, foot/ankle and sports injuries.
Since partnering with TA in 2017, Biocomposites has achieved significant growth – including a threefold increase in revenues, successful geographic expansion and continued product diversification. The company has also completed two strategic acquisitions, strengthening its international presence and enabling entry into adjacent indications and therapeutic areas. With the new investment from Novo Holdings and the ongoing support of TA, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale.
“TA has been a fantastic long-term partner to us, and we are excited for the future alongside them and Novo Holdings,” said Michael Harris, Biocomposites’ CEO. “This investment is a significant validation of Biocomposites’ achievements so far and our future prospects for growth. With the combined expertise and support of these two leading global healthcare investors, we believe we are well positioned to deliver on our commitment to bring ever more innovative products for use in infection management to more people worldwide – transforming patient outcomes and improving their lives.”
Financial terms of the transaction were not disclosed.
Source: Biocomposites
Novo Holdings and TA Associates entered into an agreement to make an investment in Biocomposites. As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the company alongside new investor Novo Holdings and Biocomposites' management. The transaction gives TA and Novo Holdings shared control of...
Novo Holdings and TA Associates entered into an agreement to make an investment in Biocomposites. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites.
Biocomposites’ pioneering calcium compounds and specialty polymer products – including STIMULAN, the only calcium matrix carrier platform approved to carry antibiotics into infected and non-infected sites in bone and soft tissue – are used by surgeons in over 100 countries worldwide. With over 30 years of expertise, Biocomposites’ solutions are used in more than one million procedures annually, across multiple specialties including musculoskeletal infection, orthopedics, trauma, spine, foot/ankle and sports injuries.
Since partnering with TA in 2017, Biocomposites has achieved significant growth – including a threefold increase in revenues, successful geographic expansion and continued product diversification. The company has also completed two strategic acquisitions, strengthening its international presence and enabling entry into adjacent indications and therapeutic areas. With the new investment from Novo Holdings and the ongoing support of TA, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale.
“TA has been a fantastic long-term partner to us, and we are excited for the future alongside them and Novo Holdings,” said Michael Harris, Biocomposites’ CEO. “This investment is a significant validation of Biocomposites’ achievements so far and our future prospects for growth. With the combined expertise and support of these two leading global healthcare investors, we believe we are well positioned to deliver on our commitment to bring ever more innovative products for use in infection management to more people worldwide – transforming patient outcomes and improving their lives.”
Financial terms of the transaction were not disclosed.
Source: Biocomposites
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
